Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of SLCO1B1 polymorphisms on plasma estrogen concentrations in women with breast cancer receiving aromatase inhibitors exemestane and letrozole.
Dempsey JM, Kidwell KM, Gersch CL, Pesch AM, Desta Z, Storniolo AM, Stearns V, Skaar TC, Hayes DF, Henry NL, Rae JM, Hertz DL. Dempsey JM, et al. Among authors: pesch am. Pharmacogenomics. 2019 Jun;20(8):571-580. doi: 10.2217/pgs-2019-0020. Pharmacogenomics. 2019. PMID: 31190621 Free PMC article. Clinical Trial.
Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells.
Michmerhuizen AR, Chandler B, Olsen E, Wilder-Romans K, Moubadder L, Liu M, Pesch AM, Zhang A, Ritter C, Ward ST, Santola A, Nyati S, Rae JM, Hayes D, Feng FY, Spratt D, Wahl D, Eisner J, Pierce LJ, Speers C. Michmerhuizen AR, et al. Among authors: pesch am. Front Endocrinol (Lausanne). 2020 Feb 11;11:35. doi: 10.3389/fendo.2020.00035. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 32117061 Free PMC article.
Short-term CDK4/6 Inhibition Radiosensitizes Estrogen Receptor-Positive Breast Cancers.
Pesch AM, Hirsh NH, Chandler BC, Michmerhuizen AR, Ritter CL, Androsiglio MP, Wilder-Romans K, Liu M, Gersch CL, Larios JM, Pierce LJ, Rae JM, Speers CW. Pesch AM, et al. Clin Cancer Res. 2020 Dec 15;26(24):6568-6580. doi: 10.1158/1078-0432.CCR-20-2269. Epub 2020 Sep 23. Clin Cancer Res. 2020. PMID: 32967938 Free PMC article.
Further Evidence That OPG rs2073618 Is Associated With Increased Risk of Musculoskeletal Symptoms in Patients Receiving Aromatase Inhibitors for Early Breast Cancer.
Hertz DL, Smith KL, Zong Y, Gersch CL, Pesch AM, Lehman J, Blackford AL, Henry NL, Kidwell KM, Rae JM, Stearns V. Hertz DL, et al. Among authors: pesch am. Front Genet. 2021 Jun 15;12:662734. doi: 10.3389/fgene.2021.662734. eCollection 2021. Front Genet. 2021. PMID: 34211496 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 34700581
[No title available]
[No authors listed] [No authors listed] PMID: 34701020
Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models.
Michmerhuizen AR, Lerner LM, Pesch AM, Ward C, Schwartz R, Wilder-Romans K, Liu M, Nino C, Jungles K, Azaria R, Jelley A, Zambrana Garcia N, Harold A, Zhang A, Wharram B, Hayes DF, Rae JM, Pierce LJ, Speers CW. Michmerhuizen AR, et al. Among authors: pesch am. NPJ Breast Cancer. 2022 Mar 10;8(1):31. doi: 10.1038/s41523-022-00397-y. NPJ Breast Cancer. 2022. PMID: 35273179 Free PMC article.
19 results